Welcome to our dedicated page for Evolus SEC filings (Ticker: EOLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evolus, Inc. (EOLS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the details. Evolus is a Nasdaq-listed performance beauty company focused on aesthetic injectables, and its filings provide formal insight into financial performance, governance, and key events affecting its Jeuveau neurotoxin and Evolysse hyaluronic acid (HA) gel portfolio.
Investors can use this page to access current and historical 10-K and 10-Q reports, which describe Evolus’ business, risk factors, and financial statements, including revenue contributions from Jeuveau and Evolysse products and discussion of non-GAAP operating metrics. Form 8-K filings, such as those announcing quarterly results or executive appointments, document material events like financial updates, leadership changes, and significant clinical or commercial milestones.
The page also surfaces Form 4 insider transaction reports, where applicable, which disclose purchases, sales, or grants of Evolus common stock by directors and officers. These filings allow users to track how insiders’ equity holdings change over time in connection with inducement grants, stock option awards, and restricted stock units described in company announcements.
Stock Titan’s AI features summarize lengthy filings into plain-language highlights, explaining how items such as non-GAAP operating income, restructuring costs, or contingent royalty obligations appear in Evolus’ disclosures. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, and 10-Ks are added as soon as they are filed, while AI-generated overviews help users quickly identify sections related to revenue trends, operating expenses, executive compensation agreements, and governance provisions. This combination of raw documents and AI analysis helps investors, analysts, and other stakeholders understand the regulatory record behind EOLS stock and the company’s performance beauty strategy.
The Vanguard Group amended its Schedule 13G to report that it beneficially owns 0 shares (0%) of Evolus Inc. common stock following an internal realignment. The filing cites the SEC Release No. 34-39538 disaggregation guidance and states certain Vanguard subsidiaries will report separately after the realignment.
The amendment clarifies voting and dispositive powers as 0 and notes the change in reporting structure that led to separate beneficial‑ownership filings by former Vanguard divisions.
Evolus, Inc. officer Rui Avelar reported an open-market sale of 3,119 shares of common stock at a weighted average price of $4.75 per share. According to the filing, these shares were sold under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations from restricted stock unit settlements. Following the sale, Avelar directly holds 427,423 Evolus shares, indicating this was a relatively small, tax-related transaction rather than a large discretionary sale.
Evolus, Inc. director and officer David Moatazedi reported an open-market sale of 13,669 shares of common stock at a weighted average price of $4.7501 per share. According to the filing, the trades were executed under a Rule 10b5-1 trading plan and were required to cover tax withholding obligations from the settlement of restricted stock unit awards. After these transactions, Moatazedi directly holds 604,700 Evolus shares, indicating this was a relatively small, tax-driven adjustment to his overall equity position.
Evolus, Inc. director and officer David Moatazedi reported a mix of equity compensation vesting and related share sales. On March 16, 2026, 67,489 performance restricted stock units (PSUs) vested and settled into the same number of common shares after achievement of 100% of target performance on a 134,977-PSU award granted on February 7, 2024. The remaining 67,488 PSUs from that grant are scheduled to vest on February 7, 2027, subject to continued service.
On March 17, 2026, he sold 116,720 shares of common stock in open-market transactions at a weighted average price of $4.8883 per share. According to the disclosure, these sales were made under a Rule 10b5-1 trading plan and were required to cover tax withholding obligations tied to the vesting and settlement of multiple PSU and restricted stock unit awards. Following these transactions, Moatazedi directly held 618,369 shares of Evolus common stock.
Evolus, Inc. executive Rui Avelar reported a routine mix of equity vesting and tax-related share sales. On March 16, 2026, 8,804 performance restricted stock units vested and converted into common shares at a conversion price of $0.0000 per share, with 8,802 PSUs scheduled to vest on February 7, 2027 subject to continued service. On March 17, 2026, he sold 29,996 common shares at a weighted average price of $4.8883 per share under a Rule 10b5-1 trading plan to cover tax withholding obligations tied to multiple PSU and restricted stock unit awards. Following these transactions, he directly holds 430,542 shares of Evolus common stock.
Evolus, Inc. reported a technical change to its board structure. After a prior director departure created an imbalance among its three director classes, the board reclassified director Vikram Malik from Class III to Class II on March 13, 2026 to restore an even distribution.
To accomplish this, Malik briefly resigned as a Class III director and was immediately reappointed as a Class II director, with his board service remaining continuous. He continues as Chairman of the Board and a member of the Compensation Committee, with no new equity awards and existing grants vesting under their original terms.
Evolus, Inc. is a global performance beauty company focused on cash-pay medical aesthetics, selling the neurotoxin Jeuveau and a line of injectable HA gels branded Evolysse. Jeuveau is approved for frown lines in multiple markets, while Evolysse Form and Smooth were approved in the United States in 2025 for wrinkles and folds.
The company targets growth in large neurotoxin and dermal filler segments but continues to post losses, with a $51.6 million net loss in 2025 and an accumulated deficit of $661.0 million. Evolus depends heavily on manufacturing and licensing partners Daewoong and Symatese, and pays Medytox royalties on Jeuveau sales, which reduces profitability.
Evolus highlights competitive pressures from larger players, regulatory and trade risks, reliance on consumer discretionary spending, and the need for additional financing if assumptions prove incorrect. As of the last reported figures, the company had an approximate market value of $560.4 million and 334 employees across the United States, Canada, Europe and Australia.
Evolus, Inc. entered a new senior secured, asset-based revolving credit facility of up to $30.0 million with Eclipse Business Capital, maturing on March 3, 2029, with an uncommitted $10.0 million accordion and a $10.0 million minimum utilization requirement.
Borrowings price at adjusted term SOFR (floor 2.0%) plus a 4.25% margin, with closing fees of 1.0% and prepayment fees starting at 3.0% and stepping down over two years. The facility is secured by substantially all company assets and includes covenants on minimum excess availability and capital expenditures.
For 2025, Evolus generated total net revenue of $297.2 million, up 12%, with Q4 revenue of $90.3 million and Q4 GAAP operating income of $4.2 million. Full-year GAAP loss from operations was $32.7 million and net loss was $51.6 million, while non-GAAP operating loss was $9.4 million. The company ended 2025 with cash of $53.8 million and total liabilities of $249.0 million, resulting in a stockholders’ deficit of $23.1 million.
Evolus projects 2026 revenue of $327–$337 million (growth of 10–13%), adjusted gross margin of 65.5–67.0% and non-GAAP operating expenses of $210–$216 million, aiming for a low- to mid-single digit Adjusted EBITDA margin in 2026 and 13–15% Adjusted EBITDA margins on $450–$500 million revenue by 2028.
Parschauer Karah Herdman reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Karah Herdman Parschauer reported an equity compensation grant in the form of restricted stock units (RSUs). The filing shows an award of 45,559 shares of common stock at a price of $0.00 per share, bringing her directly owned total to 77,742 shares.
According to the disclosure, these 45,559 RSUs each represent a contingent right to receive one share of Evolus common stock. The RSUs are scheduled to vest in full on the one year anniversary of February 17, 2026, if she remains in continuous service through the vesting date, with potential accelerated vesting in certain change-of-control and other specified events.
Stewart Brady reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director Stewart Brady reported receiving a grant of 45,559 shares of common stock in the form of restricted stock units (RSUs). The award was priced at $0.00 per share, increasing his directly held common stock (including RSUs) to 134,188 shares after the transaction.
Each RSU represents a contingent right to receive one Evolus common share. The RSUs will vest in full on the one-year anniversary of February 17, 2026, if Brady remains in continuous service through the vesting date, with potential accelerated vesting upon certain changes of control of the company.